Mandeep Singh is an Ophthalmology physician. ClinicalTrials.gov lists 16 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 N Wolfe St
Suite Maumenee 723
Baltimore, MD 212870005
Telephone
410-502-2789Registry record last updated 10 May 2016.
Clinical trials
- Point of Care Ultrasound in Pregnant Women (PoCUS-OB)
Sponsor: University Health Network, Toronto
- Effectiveness of Digital Cognitive Behavioral Therapy for Insomnia in Frontline Health Care Workers (The HCW-CBTi Study)
Sponsor: University Health Network, Toronto
- Gyrate Atrophy Ocular and Systemic Study
Sponsor: Jaeb Center for Health Research
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Pharmaceuticals, IncProgram year20251 payment
- Janssen Pharmaceuticals, IncProgram year202419 payments$28,780openpaymentsdata.cms.gov ↗
- Sumitomo Pharma America, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
96.8%Vascular Endothelial Growth Factor Inhibitor96.8%Aflibercept100%Part B, office-administered≥51 patientsSensory organs
3.2%Carbonic Anhydrase Inhibitor3.2%Dorzolamide Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2021–2025 per NIH RePORTER. The latest:
- Developing photoreceptor repair for macular degeneration therapy.
Johns Hopkins University
FY2025$347,472R01EY033103 - Developing photoreceptor repair for macular degeneration therapy.
Johns Hopkins University
FY2024$408,791R01EY033103 - Developing photoreceptor repair for macular degeneration therapy.
Johns Hopkins University
FY2023$408,791R01EY033103
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”